Transscleral cyclophotocoagulation (TSCPC) is used to treat patients with refractory glaucoma. 1,2 TSCPC is a destructive procedure of the ciliary processes leading to decreased aqueous humor production. 2 Because of complications such as hypotonia and phthisis bulbi, TSCPC is usually opted as a therapy for eyes with low visual potential and poor response to other medical or surgical interventions. 2 However, IOP changes in the very early postoperative period and its clinical implications have not been addressed yet. This study evaluates the immediate changes in intraocular pressure (IOP) after TSCPC.
In a prospective interventional design, we evaluated the changes of IOP after TSCPC in a series of 10 patients with refractory glaucoma. IOP was measured with a Tono-Pen Avira (Reichert, Buffalo, NY, USA) right before the procedure, immediately after TSCPC, 3 h, 1 day, 3 days, 7 days, and 28 days thereafter. The procedures were performed in the operating room under retrobulbar anesthesia using 2 ml of 2% lidocaine, and intravenous sedation with propofol and cardiopulmonary monitoring by anesthesia team. The starting laser parameters were power of 2000 mW and duration of 2000 ms. On the basis of the pop-sound response, power was adjusted on the steps of 250 mW. 3 All patients received subconjunctival injections of 4 mg dexamethasone at the conclusion of surgery. Those with immediate post-laser high IOP received intravenous 20% mannitol (1 g/kg). Postoperatively, all patients were instructed to use topical 1% prednisolone acetate 4 times daily (tapered over a 6 weeks period), and glaucoma medications were adjusted as required. Table 1 summarizes the patients' demographic data, laser settings, and IOP changes after TSCPC. All but one patient showed a significant increase in IOP immediately after TSCPC (mean IOP, 31.4 ± 9.8 before vs 44.3 ± 14.3 mm Hg immediately after the procedure; P = 0.012, Wilcoxon-signed rank test). Immediately after the procedure, all patients had IOP ≥ 30 mm Hg, 5 (50%) had IOP ≥ 40 mm Hg, and 3 (30%) had IOP ≥ 50 mm Hg (Table 1) . Three hours after the procedure, despite receiving the intravenous mannitol, six patients had IOP ≥ 30 mm Hg and two had IOP ≥ 50 mm Hg. However, on the first postoperative day, no patient had IOP ≥ 30 mm Hg. The pattern of IOP changes during the first month after TSCPC is depicted in Figure 1 .
The main finding of the present study was a significant IOP elevation in almost all eyes immediately after TSCPC. This could be dangerous in patients with advanced glaucomatous optic nerve damage and may result in further optic nerve injury, temporary central retinal artery occlusion, and ischemia-reperfusion retinal injury. 4 The laser-induced coagulative necrosis and disruption of ciliary processes may increase intraocular volume by creating air bubbles (which are typically heard as 'popsound' during TSCPC) 2,5 and lead to immediate IOP rise, which could not be handled properly by the impaired trabecular meshwork. The IOP elevation also happened in two patients that received only 12 spots of laser therapy Sir, Assessment of a three-generation pedigree with Fuchs endothelial corneal dystrophy with anticipation for expansion of the triplet repeat in the TCF4 gene Fuchs endothelial corneal dystrophy (FECD) has a significant genetic component to its pathogenesis and several genetic risk factors for FECD have been discovered. The first genetic risk factor for FECD, transcription factor 4 (TCF4), was detected by a genomewide association study. 1 A trinucleotide repeat, (CTG) n also known as CTG18.1, is located within an intron of the TCF4 gene. 2 Expansion of the TCF4 trinucleotide repeat is associated with FECD and expansion to 440 repeats confers a hazards ratio of 1.64 for a corneal transplant. 3 Anticipation, earlier onset of disease with increasing severity in successive generations, occurs in diseases caused by trinucleotide repeat expansions (ie, Huntington's disease). 4 Case report We investigated the potential role of TCF4 trinucleotide repeat expansion in a three-generation pedigree with a history suggestive of anticipation. FECD was diagnosed via slit lamp biomicroscopy by a board-certified ophthalmologist with cornea fellowship training, graded using a modified Krachmer scale of 0 (no disease)-6 (45 mm of central confluent guttae with corneal edema), 5 and examined via confocal microscopy (ConfoScan 4, Nidek Technologies, Fremont, CA, USA) and corneal tomography (Pentacam HR, Oculus, Lynnwood, WA, USA). Three family members were diagnosed with FECD 5 and displayed features of anticipation. The age at diagnosis occurred earlier in each successive generation, with the grandmother, mother, and daughter receiving the diagnosis of FECD at 63, 48, and 27 years of age, respectively (Figures 1 and 2 ). The severity of corneal endothelial disease was greater in each successive generation, with the grandmother, mother, and daughter displaying a modified Krachmer Grade of 2, 4, and 6, respectively, and central corneal thickness (right/left) of 535/537, 568/572, and 627/602 μm, respectively.
The size of the TCF4 trinucleotide repeat was evaluated in members of the FECD pedigree to determine if an expansion of the repeat might be the source of anticipation. The TCF4 trinucleotide repeat was amplified from family member DNA samples with the polymerase chain reaction, cloned, and sequenced using standard methods. 6 Each family member's genome has two copies of the TCF4 gene. Analysis of these DNA sequences revealed the exact number of TCF4 trinucleotide repeats in each family member's genome. The grandmother, mother, and Figure 1 Three-generation FECD pedigree. The proband is indicated with an arrow and symbol III-1, while the proband's mother and grandmother are indicated by symbols II-2 and I-2, respectively. Family members diagnosed with FECD are indicated with symbols that are shaded black. The number of TCF4 trinucleotide repeats in each family member's genome was determined by PCR amplification and DNA sequencing, and is indicated to the right of their pedigree symbol.
